Cargando…

Serodeconversion of HIV Antibody-Positive AIDS Patients Following Treatment with V-1 Immunitor

It is extremely rare when HIV seropositive adult patients experience spontaneous loss of antibodies, that is, seroreversion. The disappearance of HIV antibodies was occasionally attributed to iatrogenic intervention—serodeconversion. Such interventions include: HAART; oral interferon; Chinese herbal...

Descripción completa

Detalles Bibliográficos
Autores principales: Metadilogkul, Orapun, Jirathitikal, Vichai, Bourinbaiar, Aldar S.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577775/
https://www.ncbi.nlm.nih.gov/pubmed/18989372
http://dx.doi.org/10.1155/2009/934579
_version_ 1782160509605249024
author Metadilogkul, Orapun
Jirathitikal, Vichai
Bourinbaiar, Aldar S.
author_facet Metadilogkul, Orapun
Jirathitikal, Vichai
Bourinbaiar, Aldar S.
author_sort Metadilogkul, Orapun
collection PubMed
description It is extremely rare when HIV seropositive adult patients experience spontaneous loss of antibodies, that is, seroreversion. The disappearance of HIV antibodies was occasionally attributed to iatrogenic intervention—serodeconversion. Such interventions include: HAART; oral interferon; Chinese herbal remedies; and therapeutic AIDS vaccines derived from pooled blood. Oral therapeutic, alloimmune AIDS vaccine, V-1 Immunitor (V1), was administered to 60000 HIV-positive Thai patients. The administration of V1 resulted in serodeconversion among 23 individuals. The patient group consisted of 9 females (39%) and 14 males (61%) including two 2-year-old boys. The age range was 2–58 years with mean/median 29/29.3 years. Patients were tested seropositive for HIV at least once before being enrolled on V1. The duration of treatment until discovery of seronegative status ranged between 2 weeks and 15 months with average/median 7.2/8 months. Time to seronegativity was correlated with baseline disease stage (R = 0.62; P = .002). The seronegative status was positively associated with V1-induced undetectable or low viral load (R = 0.65; P = .0008). The odds ratio analysis comparing the outcome of our study with published surveys of diagnostic accuracy of laboratory tests suggested that the probability of HIV antibody testing error was remote (P < .000001). The possible causes responsible for this unusual phenomenon are discussed.
format Text
id pubmed-2577775
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-25777752008-11-06 Serodeconversion of HIV Antibody-Positive AIDS Patients Following Treatment with V-1 Immunitor Metadilogkul, Orapun Jirathitikal, Vichai Bourinbaiar, Aldar S. J Biomed Biotechnol Research Article It is extremely rare when HIV seropositive adult patients experience spontaneous loss of antibodies, that is, seroreversion. The disappearance of HIV antibodies was occasionally attributed to iatrogenic intervention—serodeconversion. Such interventions include: HAART; oral interferon; Chinese herbal remedies; and therapeutic AIDS vaccines derived from pooled blood. Oral therapeutic, alloimmune AIDS vaccine, V-1 Immunitor (V1), was administered to 60000 HIV-positive Thai patients. The administration of V1 resulted in serodeconversion among 23 individuals. The patient group consisted of 9 females (39%) and 14 males (61%) including two 2-year-old boys. The age range was 2–58 years with mean/median 29/29.3 years. Patients were tested seropositive for HIV at least once before being enrolled on V1. The duration of treatment until discovery of seronegative status ranged between 2 weeks and 15 months with average/median 7.2/8 months. Time to seronegativity was correlated with baseline disease stage (R = 0.62; P = .002). The seronegative status was positively associated with V1-induced undetectable or low viral load (R = 0.65; P = .0008). The odds ratio analysis comparing the outcome of our study with published surveys of diagnostic accuracy of laboratory tests suggested that the probability of HIV antibody testing error was remote (P < .000001). The possible causes responsible for this unusual phenomenon are discussed. Hindawi Publishing Corporation 2009 2008-10-28 /pmc/articles/PMC2577775/ /pubmed/18989372 http://dx.doi.org/10.1155/2009/934579 Text en Copyright © 2009 Orapun Metadilogkul et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Metadilogkul, Orapun
Jirathitikal, Vichai
Bourinbaiar, Aldar S.
Serodeconversion of HIV Antibody-Positive AIDS Patients Following Treatment with V-1 Immunitor
title Serodeconversion of HIV Antibody-Positive AIDS Patients Following Treatment with V-1 Immunitor
title_full Serodeconversion of HIV Antibody-Positive AIDS Patients Following Treatment with V-1 Immunitor
title_fullStr Serodeconversion of HIV Antibody-Positive AIDS Patients Following Treatment with V-1 Immunitor
title_full_unstemmed Serodeconversion of HIV Antibody-Positive AIDS Patients Following Treatment with V-1 Immunitor
title_short Serodeconversion of HIV Antibody-Positive AIDS Patients Following Treatment with V-1 Immunitor
title_sort serodeconversion of hiv antibody-positive aids patients following treatment with v-1 immunitor
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577775/
https://www.ncbi.nlm.nih.gov/pubmed/18989372
http://dx.doi.org/10.1155/2009/934579
work_keys_str_mv AT metadilogkulorapun serodeconversionofhivantibodypositiveaidspatientsfollowingtreatmentwithv1immunitor
AT jirathitikalvichai serodeconversionofhivantibodypositiveaidspatientsfollowingtreatmentwithv1immunitor
AT bourinbaiaraldars serodeconversionofhivantibodypositiveaidspatientsfollowingtreatmentwithv1immunitor